First-In-Class Small Molecule Modulator of Neutrophil Trafficking and Activation

Preclinical

IND Enabling

Phase 1

Phase 2

Phase 3

ADS051

Ulcerative Colitis

ADS051 is an oral, gut-restricted, small molecule modulator of neutrophil trafficking and activation for the treatment of ulcerative colitis. ADS051 blocks MRP2-mediated neutrophil trafficking into and FPR1-mediated neutrophil activation within the colonic lumen. Unlike currently available therapies, this addresses neutrophil-mediated tissue damage, a hallmark of UC pathology. In a healthy volunteer study and MAD patient study, ADS051 was safe and well tolerated and restricted to the gut with limited systemic exposure.

Publications

Featured Publications

Adiso ADS051 – Data Publications of Two Phase 1 Studies of First-in-Class Neutrophil Modulator from the American Journal of Gastroenterology